| 1 | The Dual Roles of Leucine-Rich Repeat-Containing Protein 15 Positive Fibroblasts: From Cancer to Tissue Repair | 2.3 | 4 | Citations (PDF) |
| 2 | Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosis | 6.9 | 9 | Citations (PDF) |
| 3 | Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD | 5.0 | 2 | Citations (PDF) |
| 4 | Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis | 1.9 | 5 | Citations (PDF) |
| 5 | Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort | 4.0 | 24 | Citations (PDF) |
| 6 | Antifibrotic effects of specific targeting of the 5‐hydroxytryptamine 2B receptor (5‐HT2BR) in murine models and ex vivo models of scleroderma skin | 6.1 | 4 | Citations (PDF) |
| 7 | Fibrosis: cross-organ biology and pathways to development of innovative drugs | 79.7 | 82 | Citations (PDF) |
| 8 | The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort | 3.9 | 0 | Citations (PDF) |
| 9 | Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years | 23.3 | 13 | Citations (PDF) |
| 10 | Efficacy of obinutuzumab in two rituximab refractory cases of idiopathic inflammatory myopathies with severe interstitial lung disease | 6.9 | 2 | Citations (PDF) |
| 11 | Young human alpha synuclein transgenic (BAC-SNCA) mice display sex- and gene-dose-dependent phenotypic disturbances | 2.2 | 9 | Citations (PDF) |
| 12 | Effect of Anti‐S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis–Specific Transcriptional Signatures in Human Skin | 6.1 | 23 | Citations (PDF) |
| 13 | Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical Features | 2.3 | 53 | Citations (PDF) |
| 14 | Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population | 1.6 | 3 | Citations (PDF) |
| 15 | Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics | 13.1 | 42 | Citations (PDF) |
| 16 | Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis | 12.5 | 29 | Citations (PDF) |
| 17 | Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis | 6.9 | 33 | Citations (PDF) |
| 18 | Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis | 10.6 | 58 | Citations (PDF) |
| 19 | Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions | 1.8 | 12 | Citations (PDF) |
| 20 | Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis | 3.9 | 11 | Citations (PDF) |
| 21 | miR-3606-3p alleviates skin fibrosis by integratively suppressing the integrin/FAK, p-AKT/p-ERK, and TGF-β signaling cascades | 10.5 | 16 | Citations (PDF) |
| 22 | Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model | 1.9 | 21 | Citations (PDF) |
| 23 | Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database | 1.9 | 9 | Citations (PDF) |
| 24 | Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and ResearchChest, 2023, 163, 586-598 | 1.0 | 24 | Citations (PDF) |
| 25 | Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region | 1.9 | 24 | Citations (PDF) |
| 26 | Identification of a Distinct Monocyte‐Driven Signature in Systemic Sclerosis Using Biophysical Phenotyping of Circulating Immune Cells | 6.1 | 10 | Citations (PDF) |
| 27 | Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis | 1.9 | 22 | Citations (PDF) |
| 28 | The Exciting Future for Scleroderma | 2.3 | 6 | Citations (PDF) |
| 29 | Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis | 6.1 | 41 | Citations (PDF) |
| 30 | Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis | 9.1 | 34 | Citations (PDF) |
| 31 | Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells | 6.9 | 201 | Citations (PDF) |
| 32 | Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma | 6.1 | 39 | Citations (PDF) |
| 33 | A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population | 2.4 | 10 | Citations (PDF) |
| 34 | Platelet Phagocytosis via P‐selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis | 6.1 | 32 | Citations (PDF) |
| 35 | Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score | 6.1 | 31 | Citations (PDF) |
| 36 | Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis | 6.1 | 40 | Citations (PDF) |
| 37 | LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis | 5.5 | 39 | Citations (PDF) |
| 38 | The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease | 3.5 | 21 | Citations (PDF) |
| 39 | Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial | 6.1 | 114 | Citations (PDF) |
| 40 | Patient's Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study | 2.7 | 40 | Citations (PDF) |
| 41 | Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment | 1.9 | 12 | Citations (PDF) |
| 42 | Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort | 1.9 | 42 | Citations (PDF) |
| 43 | Genetic Associations of Non–Major Histocompatibility Complex Susceptibility Loci with Systemic Sclerosis in a Han Chinese Population | 2.3 | 1 | Citations (PDF) |
| 44 | Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling | 2.4 | 3 | Citations (PDF) |
| 45 | Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects | 4.2 | 8 | Citations (PDF) |
| 46 | Dynamic changes in O-GlcNAcylation regulate osteoclast differentiation and bone loss via nucleoporin 153 | 13.9 | 36 | Citations (PDF) |
| 47 | A broad look into the future of systemic sclerosis | 3.5 | 6 | Citations (PDF) |
| 48 | Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis | 3.9 | 28 | Citations (PDF) |
| 49 | Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT | 5.5 | 52 | Citations (PDF) |
| 50 | Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis | 6.9 | 16 | Citations (PDF) |
| 51 | Reply | 6.1 | 1 | Citations (PDF) |
| 52 | Cellular and molecular mechanisms in fibrosis | 2.7 | 86 | Citations (PDF) |
| 53 | Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study | 3.4 | 10,515 | Citations (PDF) |
| 54 | Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial | 23.3 | 208 | Citations (PDF) |
| 55 | Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma | 6.9 | 52 | Citations (PDF) |
| 56 | 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study | 11.4 | 140 | Citations (PDF) |
| 57 | Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study | 11.4 | 32 | Citations (PDF) |
| 58 | X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc) | 6.9 | 13 | Citations (PDF) |
| 59 | Cytokine-mediated induction of human xylosyltransferase-I in systemic sclerosis skin fibroblasts | 2.1 | 10 | Citations (PDF) |
| 60 | Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host diseaseBlood, 2021, 137, 2403-2416 | 5.0 | 22 | Citations (PDF) |
| 61 | Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial | 3.9 | 63 | Citations (PDF) |
| 62 | Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database | 1.9 | 8 | Citations (PDF) |
| 63 | Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin | 3.4 | 7 | Citations (PDF) |
| 64 | Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis | 3.6 | 16 | Citations (PDF) |
| 65 | An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod | 3.9 | 35 | Citations (PDF) |
| 66 | TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy | 13.7 | 102 | Citations (PDF) |
| 67 | Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation | 9.3 | 47 | Citations (PDF) |
| 68 | Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome | 3.2 | 3 | Citations (PDF) |
| 69 | Purinergic signalling in systemic sclerosis | 1.9 | 1 | Citations (PDF) |
| 70 | The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease | 3.1 | 4 | Citations (PDF) |
| 71 | Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis | 6.1 | 114 | Citations (PDF) |
| 72 | Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study | 1.9 | 70 | Citations (PDF) |
| 73 | Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort | 1.9 | 23 | Citations (PDF) |
| 74 | Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis | 12.5 | 42 | Citations (PDF) |
| 75 | Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging | 6.9 | 175 | Citations (PDF) |
| 76 | cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis | 1.9 | 9 | Citations (PDF) |
| 77 | PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis | 6.9 | 38 | Citations (PDF) |
| 78 | Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis | 6.1 | 21 | Citations (PDF) |
| 79 | Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs | 2.3 | 39 | Citations (PDF) |
| 80 | The α7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders | 2.3 | 11 | Citations (PDF) |
| 81 | Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse | 6.3 | 31 | Citations (PDF) |
| 82 | Predictors of progression in systemic sclerosis patients with interstitial lung disease | 8.7 | 228 | Citations (PDF) |
| 83 | microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4 | 2.1 | 12 | Citations (PDF) |
| 84 | Therapeutic molecular targets of SSc-ILD | 1.8 | 11 | Citations (PDF) |
| 85 | TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis | 10.6 | 136 | Citations (PDF) |
| 86 | Long noncoding RNA H19X is a key mediator of TGF-β–driven fibrosis | 10.6 | 78 | Citations (PDF) |
| 87 | Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases | 2.2 | 50 | Citations (PDF) |
| 88 | Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis | 11.0 | 59 | Citations (PDF) |
| 89 | Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA‐125b in Systemic Sclerosis | 6.1 | 22 | Citations (PDF) |
| 90 | Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases | 8.7 | 256 | Citations (PDF) |
| 91 | GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways | 13.7 | 183 | Citations (PDF) |
| 92 | Shared and distinct mechanisms of fibrosis | 25.5 | 599 | Citations (PDF) |
| 93 | PU.1 controls fibroblast polarization and tissue fibrosis | 37.9 | 186 | Citations (PDF) |
| 94 | Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts | 2.3 | 19 | Citations (PDF) |
| 95 | Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc | 6.9 | 23 | Citations (PDF) |
| 96 | Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease | 1.8 | 36 | Citations (PDF) |
| 97 | Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study | 6.9 | 176 | Citations (PDF) |
| 98 | Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual | 6.9 | 27 | Citations (PDF) |
| 99 | Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs | 6.9 | 49 | Citations (PDF) |
| 100 | Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course | 2.5 | 187 | Citations (PDF) |
| 101 | Targeting TGF-β signaling for the treatment of fibrosis | 4.5 | 269 | Citations (PDF) |
| 102 | Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis | 6.9 | 44 | Citations (PDF) |
| 103 | Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators | 6.9 | 45 | Citations (PDF) |
| 104 | Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study | 6.9 | 71 | Citations (PDF) |
| 105 | Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study | 1.9 | 71 | Citations (PDF) |
| 106 | Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis | 6.9 | 17 | Citations (PDF) |
| 107 | The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis | 6.9 | 63 | Citations (PDF) |
| 108 | Innate lymphoid cells and fibrotic regulation | 2.4 | 17 | Citations (PDF) |
| 109 | NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover | 4.9 | 24 | Citations (PDF) |
| 110 | Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus | 4.9 | 12 | Citations (PDF) |
| 111 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis | 13.7 | 122 | Citations (PDF) |
| 112 | Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling | 6.9 | 33 | Citations (PDF) |
| 113 | A Dual Role of Upper Zone of Growth Plate and Cartilage Matrix–Associated Protein in Human and Mouse Osteoarthritic Cartilage: Inhibition of Aggrecanases and Promotion of Bone Turnover | 6.1 | 33 | Citations (PDF) |
| 114 | Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages | 6.9 | 94 | Citations (PDF) |
| 115 | The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc | 6.9 | 69 | Citations (PDF) |
| 116 | Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis | 6.9 | 47 | Citations (PDF) |
| 117 | Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) | 6.9 | 134 | Citations (PDF) |
| 118 | JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment | 6.9 | 52 | Citations (PDF) |
| 119 | Epigenetic Factors as Drivers of Fibrosis in Systemic Sclerosis | 2.2 | 40 | Citations (PDF) |
| 120 | Update of EULAR recommendations for the treatment of systemic sclerosis | 6.9 | 990 | Citations (PDF) |
| 121 | Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis | 13.7 | 336 | Citations (PDF) |
| 122 | Mapping and predicting mortality from systemic sclerosis | 6.9 | 652 | Citations (PDF) |
| 123 | Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis | 6.9 | 187 | Citations (PDF) |
| 124 | Tie2 as a novel key factor of microangiopathy in systemic sclerosis | 3.9 | 34 | Citations (PDF) |
| 125 | Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis | 2.7 | 34 | Citations (PDF) |
| 126 | Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis | 6.1 | 74 | Citations (PDF) |
| 127 | Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis | 6.9 | 141 | Citations (PDF) |
| 128 | Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database | 1.8 | 5 | Citations (PDF) |
| 129 | Emerging strategies for treatment of systemic sclerosis | 1.8 | 42 | Citations (PDF) |
| 130 | Updates on animal models of systemic sclerosis | 1.8 | 16 | Citations (PDF) |
| 131 | Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis | 6.9 | 44 | Citations (PDF) |
| 132 | N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis | 2.2 | 26 | Citations (PDF) |
| 133 | Evidence of innate lymphoid cell redundancy in humans | 23.5 | 295 | Citations (PDF) |
| 134 | Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross‐Disease Meta‐Analysis of Genome‐Wide Association Studies | 6.1 | 55 | Citations (PDF) |
| 135 | Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression | 6.9 | 50 | Citations (PDF) |
| 136 | Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis | 6.9 | 46 | Citations (PDF) |
| 137 | Canonical Wnt signaling in systemic sclerosis | 3.2 | 70 | Citations (PDF) |
| 138 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | 13.7 | 5,048 | Citations (PDF) |
| 139 | Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway | 6.9 | 59 | Citations (PDF) |
| 140 | Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database | 6.9 | 80 | Citations (PDF) |
| 141 | Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis | 6.9 | 33 | Citations (PDF) |
| 142 | Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis | 6.9 | 89 | Citations (PDF) |
| 143 | Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss | 6.9 | 117 | Citations (PDF) |
| 144 | Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis | 6.9 | 182 | Citations (PDF) |
| 145 | Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study | 2.3 | 226 | Citations (PDF) |
| 146 | Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis | 6.9 | 61 | Citations (PDF) |
| 147 | Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling | 6.9 | 118 | Citations (PDF) |
| 148 | Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis | 33.0 | 340 | Citations (PDF) |
| 149 | Implication of bisphosphonate use in the treatment of SAPHO syndrome: Case report and discussion of current literature | 0.6 | 11 | Citations (PDF) |
| 150 | From pathogenesis to therapy – Perspective on treatment strategies in fibrotic diseases | 9.1 | 18 | Citations (PDF) |
| 151 | Cardiomyopathy in Murine Models of Systemic Sclerosis | 6.1 | 44 | Citations (PDF) |
| 152 | Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies | 6.9 | 68 | Citations (PDF) |
| 153 | Systemische Sklerose – ein Update | 0.2 | 0 | Citations (PDF) |
| 154 | Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis | 2.3 | 22 | Citations (PDF) |
| 155 | Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages | 6.9 | 32 | Citations (PDF) |
| 156 | Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group | 6.9 | 391 | Citations (PDF) |
| 157 | S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis | 6.9 | 72 | Citations (PDF) |
| 158 | Vitamin D receptor regulates TGF-β signalling in systemic sclerosis | 6.9 | 139 | Citations (PDF) |
| 159 | Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis | 6.9 | 87 | Citations (PDF) |
| 160 | The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β and Contributes to the Development of Experimental Dermal Fibrosis | 6.1 | 15 | Citations (PDF) |
| 161 | Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability | 6.9 | 36 | Citations (PDF) |
| 162 | The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis | 6.9 | 188 | Citations (PDF) |
| 163 | Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling | 6.9 | 28 | Citations (PDF) |
| 164 | Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis | 6.5 | 209 | Citations (PDF) |
| 165 | Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? | 3.8 | 17 | Citations (PDF) |
| 166 | Activation of pregnane X receptor inhibits experimental dermal fibrosis | 6.9 | 25 | Citations (PDF) |
| 167 | The Fra-2 transgenic mouse model of systemic sclerosis | 2.5 | 64 | Citations (PDF) |
| 168 | Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis | 6.9 | 106 | Citations (PDF) |
| 169 | Tyrosine kinase signaling in fibrotic disorders | 4.1 | 113 | Citations (PDF) |
| 170 | Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling | 6.9 | 83 | Citations (PDF) |
| 171 | Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis | 6.9 | 113 | Citations (PDF) |
| 172 | Canonical Wnt signalling as a key regulator of fibrogenesis – implications for targeted therapies? | 2.7 | 59 | Citations (PDF) |
| 173 | Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors | 6.9 | 20 | Citations (PDF) |
| 174 | New insight on the Xq28 association with systemic sclerosis | 6.9 | 58 | Citations (PDF) |
| 175 | Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis | 6.9 | 40 | Citations (PDF) |
| 176 | Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover | 4.9 | 12 | Citations (PDF) |
| 177 | The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis | 2.3 | 39 | Citations (PDF) |
| 178 | The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis | 6.9 | 39 | Citations (PDF) |
| 179 | A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations | 2.9 | 79 | Citations (PDF) |
| 180 | Innovative antifibrotic therapies in systemic sclerosis | 3.6 | 49 | Citations (PDF) |
| 181 | Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis | 6.9 | 96 | Citations (PDF) |
| 182 | Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis | 6.9 | 61 | Citations (PDF) |
| 183 | Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis | 6.9 | 79 | Citations (PDF) |
| 184 | Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis | 6.9 | 80 | Citations (PDF) |
| 185 | Pomalidomide is effective for prevention and treatment of experimental skin fibrosis | 6.9 | 35 | Citations (PDF) |
| 186 | Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1 | 6.9 | 29 | Citations (PDF) |
| 187 | Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up | 2.9 | 106 | Citations (PDF) |
| 188 | Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host diseaseBlood, 2012, 120, 2909-2917 | 5.0 | 62 | Citations (PDF) |
| 189 | Inhibition of sumoylation prevents experimental fibrosis | 6.9 | 32 | Citations (PDF) |
| 190 | Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis | 2.3 | 35 | Citations (PDF) |
| 191 | Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis | 6.9 | 105 | Citations (PDF) |
| 192 | The extracellular release of DNA and HMGB1 from Jurkat T cells during
in vitro
necrotic cell death | 2.7 | 63 | Citations (PDF) |
| 193 | JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis | 6.1 | 144 | Citations (PDF) |
| 194 | Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease | 3.4 | 31 | Citations (PDF) |
| 195 | Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis | 13.7 | 796 | Citations (PDF) |
| 196 | Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis | 3.9 | 11 | Citations (PDF) |
| 197 | WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production | 4.9 | 110 | Citations (PDF) |
| 198 | Inhibition of activator protein 1 signaling abrogates transforming growth factor β–mediated activation of fibroblasts and prevents experimental fibrosis | 6.1 | 95 | Citations (PDF) |
| 199 | Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis | 6.1 | 154 | Citations (PDF) |
| 200 | β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis | 6.9 | 196 | Citations (PDF) |
| 201 | Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis | 1.6 | 30 | Citations (PDF) |
| 202 | Morphogen Pathways in Systemic Sclerosis | 4.0 | 28 | Citations (PDF) |
| 203 | Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway | 6.9 | 101 | Citations (PDF) |
| 204 | Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis | 6.9 | 147 | Citations (PDF) |
| 205 | Animal models for arthritis: innovative tools for prevention and treatment | 6.9 | 109 | Citations (PDF) |
| 206 | Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? | 3.5 | 27 | Citations (PDF) |
| 207 | Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts | 4.0 | 50 | Citations (PDF) |
| 208 | Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours | 2.2 | 18 | Citations (PDF) |
| 209 | Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis | 6.1 | 84 | Citations (PDF) |
| 210 | Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis | 6.1 | 121 | Citations (PDF) |
| 211 | Induction of apoptosis in circulating angiogenic cells by microparticles | 6.1 | 38 | Citations (PDF) |
| 212 | The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis | 6.9 | 64 | Citations (PDF) |
| 213 | Platelet-derived serotonin links vascular disease and tissue fibrosis | 9.3 | 251 | Citations (PDF) |
| 214 | Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis | 3.2 | 226 | Citations (PDF) |
| 215 | Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease | 6.9 | 24 | Citations (PDF) |
| 216 | The transcription factor Fra‐2 regulates the production of extracellular matrix in systemic sclerosis | 6.1 | 108 | Citations (PDF) |
| 217 | Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers | 6.1 | 25 | Citations (PDF) |
| 218 | MicroRNA‐29, a key regulator of collagen expression in systemic sclerosis | 6.1 | 505 | Citations (PDF) |
| 219 | Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis | 6.1 | 74 | Citations (PDF) |
| 220 | Animal models of systemic sclerosis: Prospects and limitations | 6.1 | 145 | Citations (PDF) |
| 221 | Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials | 4.0 | 41 | Citations (PDF) |
| 222 | Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis | 18.0 | 113 | Citations (PDF) |
| 223 | Lack of inhibitory effects of the anti‐fibrotic drug imatinib on endothelial cell functions in vitro and in vivo | 4.0 | 12 | Citations (PDF) |
| 224 | Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis | 6.1 | 198 | Citations (PDF) |
| 225 | The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis | 6.1 | 119 | Citations (PDF) |
| 226 | Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis | 6.1 | 110 | Citations (PDF) |
| 227 | Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases | 6.1 | 41 | Citations (PDF) |
| 228 | Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast–dependent osteoclastogenesis | 6.1 | 15 | Citations (PDF) |
| 229 | Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis | 3.9 | 119 | Citations (PDF) |
| 230 | The scientific basis for novel treatments of systemic sclerosis | 1.0 | 3 | Citations (PDF) |
| 231 | Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis | 6.1 | 117 | Citations (PDF) |
| 232 | The controversial role of tumor necrosis factor α in fibrotic diseases | 6.1 | 103 | Citations (PDF) |
| 233 | Rho‐associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts | 6.1 | 111 | Citations (PDF) |
| 234 | Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease | 6.1 | 43 | Citations (PDF) |
| 235 | The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis | 6.1 | 100 | Citations (PDF) |
| 236 | Novel Treatment Approaches to Fibrosis in Scleroderma | 2.3 | 16 | Citations (PDF) |
| 237 | Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis | 0.6 | 186 | Citations (PDF) |
| 238 | Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? | 6.9 | 21 | Citations (PDF) |
| 239 | Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis | 6.1 | 370 | Citations (PDF) |
| 240 | Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin‐induced skin fibrosis | 6.1 | 165 | Citations (PDF) |
| 241 | Microparticles stimulate the synthesis of prostaglandin E2 via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 | 6.1 | 86 | Citations (PDF) |
| 242 | Hypoxia‐induced increase in the production of extracellular matrix proteins in systemic sclerosis | 6.1 | 183 | Citations (PDF) |
| 243 | Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells | 6.1 | 91 | Citations (PDF) |
| 244 | Microparticles as mediators of cellular cross-talk in inflammatory disease | 3.1 | 160 | Citations (PDF) |
| 245 | Nucleofection: a new, highly efficient transfection method for primary human keratinocytes* | 2.7 | 53 | Citations (PDF) |
| 246 | Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis | 6.1 | 133 | Citations (PDF) |
| 247 | Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases | 6.1 | 221 | Citations (PDF) |
| 248 | The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles | 7.5 | 385 | Citations (PDF) |
| 249 | Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor-κB and Simian Virus 40 Promoter Factor 1 Pathways | 2.6 | 23 | Citations (PDF) |
| 250 | Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis | 6.1 | 103 | Citations (PDF) |
| 251 | Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis | 6.1 | 162 | Citations (PDF) |
| 252 | Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis | 13.1 | 292 | Citations (PDF) |
| 253 | Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease | 1.9 | 18 | Citations (PDF) |
| 254 | Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study | 1.9 | 7 | Citations (PDF) |
| 255 | Emerging therapies for the treatment of systemic sclerosis | 25.5 | 15 | Citations (PDF) |
| 256 | S2k-Leitlinie „Diagnostik und Therapie der systemischen Sklerose“ | 0.8 | 4 | Citations (PDF) |
| 257 | S2k-Leitlinie „Diagnostik und Therapie der systemischen Sklerose“ | 0.8 | 1 | Citations (PDF) |
| 258 | Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis | 6.9 | 3 | Citations (PDF) |
| 259 | Systemische Sklerose | 0.4 | 0 | Citations (PDF) |
| 260 | Guidance for the management of SARD-ILDs in clinical practice—impact of the ERS/EULAR recommendations | 6.9 | 1 | Citations (PDF) |
| 261 | Systemische Sklerose | 0.5 | 0 | Citations (PDF) |
| 262 | The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133) | 6.9 | 4 | Citations (PDF) |
| 263 | Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis | 25.5 | 8 | Citations (PDF) |
| 264 | High Rates of Degenerative Changes in the Lower Spine in Calcium Pyrophosphate Deposition Disease Compared to Degenerative Disc Disease | 2.3 | 0 | Citations (PDF) |
| 265 | Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database | 1.9 | 0 | Citations (PDF) |
| 266 | Low-energy small language models with retrieval-augmented generation can surpass large-model performance in rheumatology | 2.4 | 0 | Citations (PDF) |
